Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL-Frail: acalabrutinib in very old or frail patients with chronic lymphocytic leukemia
2020-002142-17Phase 2Active
- Sponsor
- University of Cologne
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Primary endpoint: Overall response rate at initial response assessment. Started Jul 2021; status: active.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2020-002142-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002142-17.